Anonymous
Guest
Anonymous
Guest
It's very simple. Launch of Belviq can put some hedge funds out of business. So they try to attack the morale of the salesforce. Belviq rocks and that's all there is to it.
It's very simple. Launch of Belviq can put some hedge funds out of business. So they try to attack the morale of the salesforce. Belviq rocks and that's all there is to it.
^ ^
^ ^
^ ^
shortie speaks
if i am not mistaken, there were around 20 million shorted shares prior to the FDA's AdCom. There are around 55 million shorted shares today - Arena shorts dug a deeper hole for themselves. Call options barely cover 25% of this position. Shorts take a huge risk here and if Eisai deliver better than the dismal Qsymia launch then they are in a big problem as Arena's share price could do them the "Harlem Squeeze". Let's just get over this weird DElAy and see what the market thinks of Belviq.
None of which would put a hedge fund firm out of business...nor would it warrant them trying to negatively 'influence' a sales force via cafe pharma.
Btw the shorts won post approval with ARNA dropping form 13 to the mid sevens…
I know facts suck.
No--- You suck, you managed care weenie! Yeah- you can't hide peckerwood. But, in the case of this silly ass arguement and the proposal that ARNA shorts would be on this CP board.... Yeah, that is a joke. You got this one right! But you are still a boner boy!